Stribild (HIV) - Forecast and Market Analysis to 2022

  • January 2013
  • -
  • Global Data
  • -
  • 39 pages

Stribild (HIV) - Forecast and Market Analysis to 2022


GlobalData has released its new PharmaPoint Drug Evaluation report, “Stribild (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Gilead’s Stribild is a complete, fixed-dose regimen for antiretroviral-treatment-naïve adults with HIV. Stribild contains two NRTIs (emtricitabine/FTC and tenofovir disoproxil fumarate/TDF), a novel INI (elvitegravir/ELV) and a novel PK enhancer (cobicistat/COBI). Stribild’s mechanism of action includes the following (Stribild prescribing information, 2012).

FTC, a synthetic nucleoside analog of cytidine, inhibits the activity of HIV reverse transcriptase (RT) by competing with a natural substrate deoxycytidine 5’-triphosphate and by being incorporated into nascent viral DNA resulting in the termination of replication.

TDF, an acyclic nucleoside phosphonate diester analog of adenosine monophosphate, is converted into its active form (i.e., tenofovir diphosphate) by normal metabolic processes. Tenofovir diphosphate inhibits the activity of the HIV RT by competing with deoxyadenosine 5’-triphosphate (a natural substrate), and terminating viral replication if the drug is incorporated into the viral DNA.

ELV inhibits the HIV integrase. This blocks HIV from integrating its DNA into host genomic DNA, which prevents HIV from replicating and propagating.

COBI enhances ELV bioavailability by selectively inhibiting cytochrome P450 enzymes of the CYP3A superfamily, which would otherwise decrease the bioavailability and half-life of ELV via metabolism. Cobicistat has no direct anti-HIV activity.


- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Stribild including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Stribild for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Stribild performance
- Obtain sales forecast for Stribild from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table Of Contents

Stribild (HIV) - Forecast and Market Analysis to 2022
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) 23
6.1 Efficacy 24
6.2 Safety 25
6.3 SWOT Analysis 25
6.4 Forecast 28
7 Appendix 29
7.1 Bibliography 29
7.2 Abbreviations 31
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 HIV Prevalence 33
7.4.2 Percent Drug-Treated Patients 33
7.4.3 General Pricing Assumptions 34
7.4.4 Individual Drug Assumptions 35
7.4.5 Generic Erosion 35
7.5 Physicians and Specialists Included in this Study 36
7.5.1 Survery of Prescribing Physicians 37
7.6 About the Authors 37
7.6.1 Authors 37
7.6.2 Global Head of Healthcare 38
7.7 About GlobalData 39
7.8 Contact Us 39
7.9 Disclaimer 39

List of Tables

Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Product Profile - Stribild 24
Table 6: Stribild SWOT Analysis, 2012 27
Table 7: Global Sales Forecasts ($m) for Stribild, 2012-2022 28
Table 8: Physicians Surveyed, By Country 37

List of Figures

Figure 1: HIV Lifecycle 11

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

2015 Opportunities in the UK Diagnostics Market

2015 Opportunities in the UK Diagnostics Market

  • $ 3 900
  • Industry report
  • February 2015
  • by Venture Planning Group

This new report from provides an overview of the UK diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume ...

 HIV-Associated Lipodystrophy Syndrome-Pipeline Insights, 2015

HIV-Associated Lipodystrophy Syndrome-Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, HIV-Associated Lipodystrophy Syndrome- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the HIV-Associated Lipodystrophy Syndrome. The main ...

The 2016-2021 World Outlook for Human Immunodeficiency Virus (HIV) Treatments

The 2016-2021 World Outlook for Human Immunodeficiency Virus (HIV) Treatments

  • $ 995
  • Industry report
  • April 2015
  • by ICON Group

This econometric study covers the world outlook for human immunodeficiency virus (HIV) treatments across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential ...

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US - Forecast

  • May 2015
    3 pages
  • Pathology  


    Hepatitis C  

  • United States  

View report >

Travel Industry in Canada

  • May 2015
    27 pages
  • Travel  


  • Canada  

View report >

Pathology Description in the US

  • May 2015
    15 pages
  • Eye Disease  

  • United States  

View report >

Pathology Description

21 days ago

Related Market Segments :


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.